Irisin in the Glucose Continuum

Assyov, Yavor; Gateva, Antoaneta; Tsakova, Adelina; Kamenov, Zdravko

doi:10.1055/s-0035-1564130

Cited by 14 publications

(15 citation statements)

References 32 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distribution of fat to the legs and trunk has recently shown differential genetic associations between sexes: a greater capacity for peripheral adipose storage in women parallels a lower risk of CV and metabolic disease [25]. However, irisin levels did not differ with respect to the presence of MetS in both gender groups, as previously reported in younger subjects with a wider range of glucose tolerance and BMI levels [26].…”

Section: Discussionsupporting

confidence: 67%

Irisin and markers of metabolic derangement in non-diabetic Caucasian subjects with stage I-II obesity during early aging

et al. 2020

View full text Add to dashboard Cite

Irisin concentrations are decreased in subjects with overt diabetes and upregulated in those with obesity or impaired fasting glucose. However, gender-balanced data in older populations, in whom risk factors commonly culminate in overt cardiovascular disease, are scarce. We assessed in non-diabetic Caucasian subjects with stage I-II obesity in the early aging range (50 to 70 years), the relationship between irisin, body composition and markers of metabolic derangement by gender. In 60 (31 women, 29 men) non-diabetics with a body mass index �30 -�40 kg/m 2 , we measured anthropometrics and body composition (Air Displacement Plethysmography). We assayed lipid and glucose profile by routine methods, plasma irisin by ELISA and measured insulin resistance by the HOMA index. Irisin levels were higher in women than in men (161 [105-198]) vs 83 [33-115] ng/ml, P<0.001), and correlated directly with HOMA index in both (rho 0.735, P<0.001 M, rho 0.452, P = 0.011 F). Sex differences were maintained across insulin resistance severity stages. In men, irisin concentrations correlated directly with body mass index (rho 0.755, P<0.001), waist circumference (rho 0.623, P<0.001), fat mass index (rho 0.762, P<0.001), glucose (rho 0.408, P = 0.028), the fatty liver index (rho 0.705, P<0.001) and FINDRISC score (rho 0.536, P = 0.003). Among non-diabetic Caucasian subjects with obesity in the early stages of aging, irisin levels reflect the amount of body fat and insulin resistance severity, independently of between-gender differences in the adipomyokine concentrations and are associated with markers of visceral adiposity in men but not in women. Citation: Campolo J, Corradi E, Rizzardi A, Parolini M, Dellanoce C, Di Guglielmo ML, et al. (2020) Irisin and markers of metabolic derangement in non-diabetic Caucasian subjects with stage I-II obesity during early aging. PLoS ONE 15(2): e0229152. https://doi.org/10.

show abstract

Section: Discussionsupporting

confidence: 67%

Irisin and markers of metabolic derangement in non-diabetic Caucasian subjects with stage I-II obesity during early aging

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Regarding type 2 diabetes mellitus, most of the published studies including two meta-analyses concluded that irisin is decreased in comparison with non-diabetic controls [7][8][9][10][11][12][13], while one study reported that there is no association between irisin and type 2 DM [33]. Similarly, in prediabetes two studies showed that irisin is decreased in individuals with prediabetes as compared to subjects with normal glucose levels [14,15].…”

Section: Discussionmentioning

confidence: 99%

“…that irisin is increased in obesity [6], and is decreased in individuals with type 2 diabetes [7][8][9][10][11][12][13] or prediabetes [14,15]. Nevertheless, data regarding levels of circulating insulin in subjects with type 1 diabetes mellitus (T1DM) are still limited.…”

Section: Introductionmentioning

confidence: 99%

Plasma Irisin Levels in Subjects with Type 1 Diabetes: Comparison with Healthy Controls

et al. 2018

View full text Add to dashboard Cite

Irisin is a myokine that increases energy expenditure. In this cross-sectional study, we examined for differences in plasma irisin concentrations between subjects with type 1 diabetes mellitus and healthy individuals and searched for associations between plasma irisin levels and clinical and biochemical characteristics as well as self-reported physical activity. A total of 79 subjects with type 1 diabetes [age 38.2±12.5 years, men/women (n): 27/52], were consecutively recruited. Moreover, 53 healthy controls, matched for age and body mass index with those with diabetes were recruited. Plasma irisin was measured with ELISA. Participants were asked about their physical activity during the last week. We also measured trunk and visceral fat. Circulating irisin levels were lower in subjects with diabetes than in controls [median value (interquartile range): 53.0 (35.2, 106.3) vs. 178.1 (42.6, 641.6) ng/ml, respectively, p<0.001]. In the group of diabetes, univariate analysis showed that irisin levels were associated with waist circumference (beta=–0.283, p=0.023), serum triglycerides (beta=–0.282, p=0.031), and trunk fat (beta=–0.324, p=0.012). In multivariate analysis after adjustment for potential confounders, irisin levels were associated independently only with waist circumference (beta=–0.403, p=0.005). Among controls, multivariate analysis demonstrated that irisin levels were associated with pack-years of smoking (beta=–0.563, p=0.012) and fasting triglycerides (beta=–0.338, p=0.041). Circulating irisin levels were lower in subjects with diabetes in comparison with healthy-matched controls. In conclusion, plasma irisin concentrations in subjects with diabetes were associated with waist circumference, while in controls with serum triglycerides and pack-years of smoking.

show abstract

“…Testosterone concentration was measured using an electrochemiluminescent method (Elecsys, Roche Diagnostics™). More detailed information on the methodology used can be found in another study by our team as it is similar to what was used in the current one [26].…”

Section: Biochemical Measurementsmentioning

confidence: 99%

Irisin and Testosterone in Men with Metabolic Syndrome

et al. 2017

View full text Add to dashboard Cite

The beneficial effects of testosterone on the metabolism and body composition of men are well established but the exact mechanisms of these effects are not clearly understood. A potential explanation might lie in the hormones, secreted from skeletal muscles, named "myokines". One such myokine, irisin, has been shown to also have potential beneficial metabolic effects. The aim of this pilot study was to evaluate the association of serum testosterone with circulating serum irisin levels in men with metabolic syndrome. A total 128 men with metabolic syndrome (MS) based on the IDF criteria participated in the study. Irisin serum concentration was determined by means of ELISA. Mean age±SD of the study participants was 51.8±8.3 years. Seventy percent of the subjects had type 2 diabetes mellitus. Circulating irisin was inversely associated with serum testosterone (r=-0.279, p<0.01) and was significantly higher in subjects with hypogonadism - mean±SD 252.0±147.1 vs.172.9±92.2 ng/ml (p=0.002). ROC analysis of serum irisin value was determined for distinguishing subjects with hypogonadism (AUC=0.670). In a multiple linear regression model with BMI, FPG, age, and irisin, only BMI (β=-0.228, p=0.004) and irisin (β=-0.170, p=0.045) were variables independently associated with testosterone concentrations. Irisin is negatively associated with serum testosterone in our population sample of men with MS. This might suggest a possible involvement of myokines and testosterone with regards to the human metabolism. As no such data on this association has been reported in the literature thus far, further prospective studies are required to elucidate this correlation.

show abstract

Irisin in the Glucose Continuum

Abstract: Circulating irisin levels progressively decreased with the worsening of the glucose tolerance. Irisin correlated well with traditional biochemical and anthropometric parameters of metabolic health.

Cited by 14 publications

References 32 publications

Irisin and markers of metabolic derangement in non-diabetic Caucasian subjects with stage I-II obesity during early aging

Irisin and markers of metabolic derangement in non-diabetic Caucasian subjects with stage I-II obesity during early aging

Plasma Irisin Levels in Subjects with Type 1 Diabetes: Comparison with Healthy Controls

Irisin and Testosterone in Men with Metabolic Syndrome

Contact Info

Product

Resources

About